tag sec 
pharmaphorum
AUGUST 21, 2022
The biotech hasn’t revealed much information about the reasons for the delay in getting approval, but said in an SEC filing in June this year that it had agreed to “post-marketing commitments” proposed by the FDA, without going into details.
Pharmaceutical Technology
NOVEMBER 9, 2022
In its October 28 quarterly Securities and Exchange Commission (SEC) filing, the company said that Roctavian’s commercial launch is now underway. million price tag. The post Can gene therapies for haemophilia defend their high price tags? BioMarin previously said that the treatment’s European price would likely be around EUR1.5
Expert insights. Personalized for you.
97 
Let's personalize your content